European public health agencies evaluate antibiotic resistance of Staphylococcus aureus

The European Medicines Agency (EMEA)The European Food Safety Authority (EFSA), the European Centre for Disease Control and Prevention (ECDC) and the European Medicines Agency (EMEA) have published today a joint Scientific Report on meticillin resistant Staphylococcus aureus (MRSA) in livestock, pets and foods.

Following a request from the European Commission, EFSA's Panel on Biological Hazards and ECDC concluded that food-producing animals such as pigs, veal calves and broiler chickens often carry without symptoms a specific strain of MRSA called CC398. However, while food may be contaminated by MRSA there is currently no evidence that eating or handling contaminated food can lead to an increased health risk for humans. The report also noted that people in contact with live animals that carry the CC398 strain of MRSA could be at risk of infection. This specific strain of MRSA has been associated, albeit rarely, with serious skin and soft tissue infections, pneumonia and blood poisoning in humans. Pet animals can also be infected with MRSA, where the bacteria first pass from humans to pets and then back to humans. The document noted the importance of basic hygiene measures, especially hand washing before and after contact with animals, and if possible, avoiding direct contact with nasal secretions, saliva and wounds.

The report concluded that as animal movement and contact between live animals and humans are likely to be important factors in the transmission of MRSA, the most effective control measures will be at farm level.

In a parallel review, the European Medicines Agency looked at the risk of colonisation or infection of livestock and companion animals with MRSA in the context of the authorisation and the use of antimicrobial veterinary medicines. The Committee for Medicinal Products for Veterinary Use (CVMP) found that MRSA is resistant to virtually all antibiotics from the beta-lactam group(1), and very often also to other antimicrobials. Prudent use of antimicrobials in animals should remain a key measure and the CVMP recommended monitoring of animal consumption of antimicrobials to identify any sources of unnecessary use. The Committee also recommended that medicines of last resort for MRSA treatment in humans should be avoided in animals, so as to ensure their continued efficacy in humans.

MRSA infections are widespread in hospitals in many EU Member States and are a major cause of hospital-acquired infections which can lead to severe illness and in some cases fatalities. In recent years a link has also been established between MRSA in animals and human MRSA infections. In the areas of the EU where MRSA is found amongst food producing animals, people in contact with these animals, such as farmers, veterinarians and their families, are at risk of acquiring an MRSA infection. Given the severity of some MRSA infection, ECDC is supportive of measures to ensure prudent use of antibiotics in food producing animals. Through the European Antibiotic Awareness Day initiative, ECDC is actively engaged in initiatives to raise awareness about the risks associated with inappropriate use of antibiotics and how to use antibiotics responsibly.

For further information on the work of ECDC, EFSA and EMEA:

1. Beta-lactam antibiotics are a broad class of widely-used antibiotics which include amongst others penicillin derivatives, cephalosporins, monobactams and carbapenems.

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...